RECRUITING

Rare and Atypical Diabetes Network

Talk to us

Conditions

Diabetes MellitusDiabetes Mellitus ProgressionGlucose IntoleranceGlucose Metabolism DisordersMetabolic DiseaseEndocrine; ComplicationsEndocrine System DiseasesRADIANTAtypical DiabetesRare Diabetes

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

RADIANT is a network of 14 clinical sites and several laboratories dedicated to the study of atypical diabetes. The objective of this study is to define new forms of diabetes and the unique mechanisms underlying these forms of atypical diabetes. The specific aims are to: 1. Identify and enroll individuals and families with undiagnosed rare and atypical forms of diabetes. 2. Determine the etiologic basis of the metabolic disorder among individuals and families with novel forms of rare and atypical diabetes. 3. Understand the pathophysiology of individuals and families with novel forms of rare and atypical forms of diabetes.

Official Title

Rare and Atypical Diabetes Network

Quick Facts

Study Start:2020-09-30
Study Completion:2030-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05544266

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Type 2 diabetes diagnosed at a time when the individual was prepubertal or non-obese
  2. * Mendelian pattern, especially with early onset (\<18 years old)
  3. * Syndromic (multiple systems involved)
  4. * Lipodystrophic
  5. * Extremes of BMI
  6. * "Mitochondrial" characteristics (e.g., myopathy, hearing deficits)
  7. * Non-progressive
  8. * Rapidly progressive ("fulminant")
  9. * Low insulin requirements (\<0.5 u/kg/day)
  10. * Cyclical hyperglycemia with periods of remission
  11. * Lean persons with polycystic ovarian syndrome (PCOS)
  12. * History of gestational diabetes (GDM) when lean
  13. * Lean insulin-resistant persons
  14. * If islet autoantibodies and beta-cell function parameters have been measured (where "A" = islet cell autoantibodies, "B" = beta-cell function):
  1. * Those with high likelihood of typical type 1, typical type 2, known monogenic, or other known secondary forms of diabetes
  2. * Refusal of consent for genetic testing
  3. * Islet autoantibody positive (participants who are islet autoantibody positive but present with additional atypical features i.e. syndromic, strong linear family history of diabetes may not be excluded)
  4. * Women who are currently pregnant

Contacts and Locations

Study Contact

Jeffrey Krischer, PhD
CONTACT
813-396-9501
contact@atypicaldiabetesnetwork.org

Principal Investigator

Jeffrey Krischer, PhD
STUDY_CHAIR
University of South Florida

Study Locations (Sites)

University of Colorado- Denver
Aurora, Colorado, 80045
United States
University of Chicago
Chicago, Illinois, 60637
United States
Indiana University
Indianapolis, Indiana, 46202
United States
University of Maryland
Baltimore, Maryland, 21201
United States
Massachusetts General Hospital (MGH)
Boston, Massachusetts, 02114
United States
University of Michigan
Ann Arbor, Michigan, 48109
United States
Washington University in St. Louis
Saint Louis, Missouri, 63110
United States
SUNY Downstate Health Sciences University
Brooklyn, New York, 11203
United States
Columbia University
New York, New York, 10032
United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514
United States
Vanderbilt University
Nashville, Tennessee, 37232
United States
Baylor College of Medicine
Houston, Texas, 77030
United States
Seattle Children's
Seattle, Washington, 98105
United States
University of Washington
Seattle, Washington, 98109
United States

Collaborators and Investigators

Sponsor: University of South Florida

  • Jeffrey Krischer, PhD, STUDY_CHAIR, University of South Florida

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-09-30
Study Completion Date2030-09

Study Record Updates

Study Start Date2020-09-30
Study Completion Date2030-09

Terms related to this study

Keywords Provided by Researchers

  • RADIANT
  • Atypical Diabetes
  • Rare Diabetes
  • Glucose Intolerance

Additional Relevant MeSH Terms

  • Diabetes Mellitus
  • Diabetes Mellitus Progression
  • Glucose Intolerance
  • Glucose Metabolism Disorders
  • Metabolic Disease
  • Endocrine; Complications
  • Endocrine System Diseases